ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings


RSS Latest in Cardiology from ACC.org

  • Can Plasma Infrared Molecular Fingerprinting Stratify Residual Risk in Patients With CAD?
    Plasma infrared molecular fingerprinting (IMF) is able to stratify residual mortality risk in patients with coronary artery disease (CAD), outperforming guideline-recommended SMART2 scores and capturing clonal haematopoiesis of indeterminate potential (CHIP)-associated biology without the need for genomic sequencing...
  • ATTR-CM: Sex Differences, Delayed Diagnosis and Effect of Acoramidis
    Three recent studies, two published in JACC: Advances and a third published in JAMA Cardiology, investigate sex differences, delayed diagnosis and the effect of acoramidis on heart failure (HF)-related health status in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
  • ADVANCE OUTCOMES: Ralinepag Reduces Clinical Worsening For PAH
    Ralinepag, a selective prostacyclin IP receptor agonist, significantly reduced the risk of first clinical worsening compared with placebo in patients with pulmonary arterial hypertension (PAH) but was associated with more adverse-event-related treatment discontinuations, according to results of the ADVANCE OUTCOMES trial published July 28 in The Lancet.
  • PARTNER 3: 7-Year TAVR vs. SAVR Outcomes in Low-Risk Patients
    Both TAVR and SAVR were associated with a sustained, substantial improvement in patient-reported health status among patients with severe aortic stenosis (AS) considered at low risk, according to the seven-year outcomes of the PARTNER 3 trial published July 29 in JACC.
  • JACC CKM Guideline Spotlight Issue Addresses Obesity, HF Prevention, More
    The recent release of the 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome marked an important step in defining evidence-based approaches to CKM prevention, risk assessment and treatment.